Lindbrook Capital, LLC Iveric Bio, Inc. Transaction History

Lindbrook Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	SELL	$26.24 - $39.63 $418,055 - $631,385	-15,932 Reduced 97.5%	409 $16,000
Q1 2023 Apr 26, 2023	SELL	$18.67 - $24.56 $1,904 - $2,505	-102 Reduced 0.62%	16,341 $397,000
Q4 2022 Jan 24, 2023	BUY	$17.24 - $23.95 $5,327 - $7,400	309 Added 1.92%	16,443 $0
Q3 2022 Nov 10, 2022	BUY	$9.4 - $18.59 $413 - $817	44 Added 0.27%	16,134 $289,000
Q2 2022 Aug 01, 2022	BUY	$9.12 - $18.9 $1,048 - $2,173	115 Added 0.72%	16,090 $155,000
Q4 2021 Jan 18, 2022	BUY	$13.83 - $18.78 $209,870 - $284,986	15,175 Added 1896.88%	15,975 $267,000
Q3 2021 Nov 05, 2021	BUY	$7.07 - $17.5 $5,656 - $14,000	800 New	800 $13,000
Q3 2020 Nov 03, 2020	SELL	$4.01 - $6.29 $8,020 - $12,580	-2,000 Closed	0 $0
Q2 2020 Jul 27, 2020	BUY	$3.06 - $6.6 $6,120 - $13,200	2,000 New	2,000 $10,000
Q1 2020 Apr 22, 2020	SELL	$2.83 - $8.44 $8,490 - $25,320	-3,000 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$0.93 - $8.58 $2,790 - $25,740	3,000 New	3,000 $26,000

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.